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Promoting quality use of medicines in
South-East Asia: reports from country
situational analyses
Kathleen Anne Holloway1,2* , Anita Kotwani3, Gitanjali Batmanabane4, Budiono Santoso5,
Sauwakon Ratanawijitrasin6 and David Henry7,8
Abstract
Background: Irrational use of medicines is widespread in the South-East Asia Region (SEAR), where policy implementation
to encourage quality use of medicines (QUM) is often low. The aim was to determine whether public-sector QUM is better
in SEAR countries implementing essential medicines (EM) policies than in those not implementing them.
Methods: Data on six QUM indicators and 25 EM policies were extracted from situational analysis reports of 20
country (2-week) visits made during 2010–2015. The average difference (as percent) for the QUM indicators
between countries implementing versus not implementing specific policies was calculated. Policies associated
with better (> 1%) QUM were included in regression of a composite QUM score versus total number of policies
implemented.
Results: Twenty-two policies were associated with better (> 1%) QUM. Twelve policies were associated with 3.6–
9.5% significantly better use (p < 0.05), namely: standard treatment guidelines; formulary; a government unit to
promote QUM; continuing health worker education on prescribing by government; limiting over-the-counter
(OTC) availability of systemic antibiotics; disallowing public-sector prescriber revenue from medicines sales; not
charging fees at the point of care; monitoring advertisements of OTC medicines; public education on QUM; and a
good drug supply system. There was significant correlation between the number of policies implemented out of
22 and the composite QUM score (r = 0.71, r2 = 0.50, p < 0.05).
Conclusions: Country situational analyses allowed rapid data collection that showed EM policies are associated
with better QUM. SEAR countries should implement all such policies.
Keywords: South-East Asia, Quality use of medicines, Essential medicines policy
Background
Inappropriate (irrational, incorrect, improper, poor qual-
ity) use of medicines is a serious public health problem
world-wide [1–5] that wastes resources and may result
in treatment failure and avoidable adverse drug events,
including antimicrobial resistance [6–8], hospitalisation
and death [9–11]. The World Health Organisation
(WHO) has been promoting the concept of essential
medicines and a range of policies to promote better
quality (rational) use of medicines (QUM) for many
years [12, 13]. The extent to which countries, including
many in South-East Asia, monitor use or implement
these recommended policies vary greatly [14, 15]. A re-
view of interventions to promote better QUM in low
and middle-income countries found that relatively few
had been implemented and that most were small scale
of short duration with small or modest effect [4, 5].
Analysis of secondary data on public-sector medicines
use in primary care (from WHO’s database of medicines
use surveys) and policy implementation as reported by
Ministries of Health (MOH) (from questionnaires sent
to Ministries of Health by WHO) showed that many es-
sential medicines policies are associated with better
QUM and that the more policies are implemented the
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better the use [16, 17]. Policies most strongly associated
with QUM were: undergraduate training of doctors and
nurses in standard treatment guidelines, the ministry of
health having a unit promoting QUM, and provision of
essential medicines free at point of care to all patients
[16, 17].
The need for an integrated health systems approach,
incorporating regular monitoring of medicines use and
the sustainable implementation of multiple policies has
long been recognised [18, 19]. However, development of
such an approach remains elusive in many low and
middle-income countries, where data are scant, infra-
structure is lacking and responsibility for medicines
management often falls between different departments
with no clear accountability [20].
Since 2010 South-East Asian countries of the WHO
have been undertaking 4-yearly rapid situational analyses
of how medicines are used and managed with a view to
developing a more integrated, coordinated health sys-
tems approach to promoting better QUM [21]. This
process consists of rapid systematic data collection on
medicines use and policy implementation by a multi-
disciplinary government team of four to eight people
over 2 weeks using a predesigned workbook tool and
ending with a national workshop to identify priorities
for action [21]. During 2010–2015, all 11 jurisdictions
(all South-East Asia countries including two Indian
States) had conducted at least one situational analysis;
eight had conducted two situational analyses sepa-
rated by a period of 4 years; and the reports pub-
lished on the WHO’s South-East Asia Regional Office
(SEARO) website after government approval [21].
The aim of this paper was to investigate associations
between the adoption (implementation or partial imple-
mentation) of national policies intended to improve
QUM and patterns of medicine use in WHO South-East
Asian countries. The analysis relies on data on medi-
cines use in public-sector primary care, and policy im-
plementation, extracted from the country situational
analysis reports [21]. Specific objectives were to establish
for the WHO South-East Asia region:
1. which policies are associated with better QUM,
2. whether the implementation of more policies is
associated with better QUM, and
3. whether there was any improvement in policy
implementation and QUM in countries that had
undertaken two situational analyses.
Methods
The country reports of the situational analyses published
on the website of the WHO Regional Office for
South-East Asia (WHO/SEARO) [21] were reviewed and
data extracted on QUM in public-sector primary care
and the implementation of policies to encourage appro-
priate use. The methods for conducting country situ-
ational analyses have been described elsewhere [21,
22] and are summarised in Table 1. Briefly, data on
policy implementation was collected by interviews of
health staff and observation, and data on QUM by
prescription survey following the International Net-
work for the Rational Use of Drugs (INRUD)/WHO
methodology [23, 24] at all the health facilities visited.
The methods used to analyse the extracted data
followed similar methods used by first author in
analysing global data and are described elsewhere [16,
17] and summarised below.
A dataset was created (Additional file 1) consisting of
six standard QUM indicators [16, 17] and indicators for
implementation of 25 policies hypothesised to influence
Table 1 Summary of methods used in a country situational
analysis
Background
Development of the situational analysis approach in South-East Asia
was requested by Member States [38, 39] and involves the systematic
collection of data by a government multi-disciplinary team over 2
weeks using a pre-designed workbook tool [21] and supervised by
WHO. The workbook tool (Additional file 2) builds on other tools
[14, 23, 24] and was developed by WHO/SEARO during situational
analyses done in 11 countries during 2010–13 and piloted for use by
government staff in eight countries during 2014–15.
Methods
Visits are made to:
• all major MOH units and other agencies responsible for medicines
management (supply, selection, use, regulation, policy, insurance
and professional training) to understand what policies are in place
and what each unit does.
• healthcare facilities, aiming to visit 20 facilities, two of each type of
public facility (primary care centres and sub-centres, secondary and
tertiary hospitals, with half of the facilities being primary care
centres) plus private pharmacies (results not reported in this paper)
in at least two provinces/regions, as selected by the MOH.
Data collection and Analysis
At the central level, staff are interviewed about the health system,
what their unit does and what policies are in place.
At each health facility (whether hospital or health centre), the team
reviews 30 primary care outpatient encounters (using whatever
documentation is available at the facility, e.g. prescriptions held in the
pharmacy or by the patient, paper slips in the pharmacy, patient
records, or outpatient registers). The means for standard indicators of
medicines use [23, 24] are calculated for each facility and each
category of facility. Also, antibiotic use in 30 outpatient cases of upper
respiratory tract infection is reviewed, although this is difficult in some
countries where diagnosis is not recorded on the prescription. The
basis for a diagnosis of upper respiratory tract infection is also
recorded e.g. acute viral respiratory infection, pharyngitis, sore throat,
rhinitis, runny nose, cough, cold, otitis media, earache, sinusitis, acute
laryngitis and acute bronchitis.
The medicines’ supply and regulatory systems are also reviewed and
health workers interviewed about medicine management policy
implementation.
A descriptive analysis is done each day and presented by the team at
a national workshop at the end of 2 weeks, and a country report
published on the WHO/SEARO website after government approval
[21, 38].
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medicines use [14–17], derived from data collected dur-
ing 20 country situational analysis visits. Since different
provinces or regions and different healthcare facilities
were visited in the countries where two situational ana-
lyses were done, and the visits were separated by 3–
5 years (during which time the implementation of some
policies changed), these situational analyses were treated
as separate records (country-year jurisdictions) in the
dataset.
The QUM indicators (described in Table 2, together
with the direction of more appropriate use) are all
expressed as proportions and include all the indicators
measured in the country situational analyses apart from
one (the average number of drugs per patient). In the
situational analysis reports [21], QUM indicators were
reported as an average for each facility type, but for this
analysis one result per QUM indicator was calculated,
this being the average across all facilities.
The policy indicators (described in Table 3) are all
expressed as categorical yes/no variables and include
all those policies hypothesised to improve the appro-
priate use of medicines [16, 17] for which data were
available in the country situational reports [21] and
for which there were countries with and without the
policy (for comparison). Some policies hypothesised
to influence prescribing were not implemented by any
country (e.g. monitoring all drug promotional activ-
ities), but if possible, similar more limited policies
were substituted (e.g. monitoring of advertisements
restricted to over-the-counter drugs). Where policy
implementation was expressed as a range of values,
the policy was converted to a yes/no value. For ex-
ample, “some” public education and “some” health
worker training was regarded as “yes” when assessing
whether a country had implemented these policies.
Details of decisions on whether a policy was marked
as present or not can be seen in Table 3. Since coun-
try wealth may be a potential confounder (being asso-
ciated with both better QUM and greater policy
implementation), data on gross national income per
capita (GNIpc) were extracted for each country in the
year of the situational analysis from the United
Nations (UN) Country Profile Data [25].
Analyses
Analyses were done in Excel 2016 and Epi Info version
7.2.1.0. Univariate analyses, with each policy as the unit
of analysis, were used to identify policies that were asso-
ciated with better QUM. The mean difference (expressed
as a percentage) for each QUM indicator between
“countries” (country-year jurisdiction) implementing and
not implementing a specific policy was calculated. The
directionality of “better” or “worse” use was aligned for
each of the six QUM indicators and an average (overall)
difference calculated for each specific policy, whereby a
positive (+) number indicates “better” use and a minus
(−) number indicates “worse” use. The mean differences
for each QUM indicator, and the average difference
across all QUM indicators for each policy were calcu-
lated and represent an estimate of the quantitative
impact of each policy. Head-to-head comparisons of the
impact of different policies and further multiple compar-
isons were not done.
Correlations of multiple policies with QUM indicators,
where the “country-year jurisdiction” was the unit of
analysis, were performed to see if adoption (implementa-
tion or partial implementation) of more policies was
associated with better QUM. Since various policies are
likely to impact differently on different QUM indicators,
and to gain an idea of the overall impact on QUM by
the package of policies that any one country was imple-
menting in one specific year, a composite QUM variable
was derived, in the same manner as has been done else-
where [16]. Use of a composite QUM variable allowed
comparison of data across all 20 situational analyses
rather than only 15, since some QUM indicators were
not measured in five situational analyses. For each indi-
vidual QUM variable, we calculated how far that coun-
try’s value (referred to as “country-year” – see text) lay
above or below the mean value from all “country-years”
and then converted this difference into standard devi-
ation units. The average of the standard deviation unit
increments across all six QUM indicators for each
country-year was calculated and this was then regressed
against the number of implemented policies that were
associated with an effect size of more than 1% (22 out of
25 policies) as estimated from the univariate analysis.
Although countries implement each policy differently,
the adoption of more policies is likely to reflect stronger
intention to promote QUM, which may be reflected
variously by different QUM indicators. Hence, individual
QUM indicators were also regressed on the number of
policies a country implemented. Since there may be
Table 2 Quality Use of Medicines (QUM) indicators and direction
of better use
QUM Indicator Direction of better
use
% Upper Respiratory Tract Infection (URTI) cases
(patients) treated with antibiotics
Less
% cases (patients) treated with antibiotics Less
% prescribed medicines from the national Essential
Medicines List (EML)
More
% medicines prescribed by generic name More
% cases (patients) treated with multivitamins Less
% cases (patients) treated with an injection Less
Six standard indicators of quality of medicines use [23, 24] expressed as
proportions and reported in 85–100% of the situational analyses
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Table 3 Medicine Policy variables with information on how a policy was judged to be present or not
Policies recommended to improve medicines usea Criteria to determine whether a policy was adopted (implemented or partially
implemented) in a country
National structures, medicines policies and monitoring
1 National MOH unit on promoting rational use of medicines Policy was marked “yes” if there was any unit, even if very small and consisting of
only 1–2 persons, or an executive committee with responsibility for promoting quality
use of medicines.
2 Presence of a Drug and Therapeutic Committee (DTC) in
most referral hospitals
Policy was marked “yes” if more than half of referral hospitals visited had a DTC
which had met in the last year (even if not very active) and there was an MOH
mandate for DTCs.
3 National strategy to contain antimicrobial resistance Policy was marked “yes” if there was any policy document endorsed by MOH on
AMR containment.
4 Presence of National Drug Information Centre Policy was marked “yes” if any national drug information centre existed, even if the
centre was not very active and did not offer 24-hour emergency information.
5 Prescription audit in the last 2 years Policy was marked “yes” even if the audit had only been undertaken in the health
facilities of some districts, but including at least one of the districts visited during
the situational analysis.
Educational policies
6 Undergraduate training of prescribers on the National
Essential Medicines List (EML)
Policy was marked “yes” even if only some training institutions included the EML in
the curriculum.
7 Undergraduate training of prescribers on the National
Standard Treatment Guidelines (STGs)
Policy was marked “yes” even if only some training institutions included the STG in
the curriculum.
8 Continuing medical education (CME) of prescribers by
MOH
Policy was marked as “yes” even if only some prescribers received CME on general
prescribing in adults and/or children. The Antibiotic SMART Use program in
Thailand, INRUD training activities in Nepal and the training activities of the
National Institute of Health (INS) in Timor-Leste are examples of CME by the MOH
[21, 37].
9 Public education on medicines use in last 2 years Policy was marked “yes” if any district populations had received public education.
Managerial Policies
10 National Essential Medicines List updated in the last 2 years Was not hypothesized to influence antibiotic use.
11 National Standard Treatment Guidelines updated in the last
2 years
Policy was marked” yes” if there was any kind of officially published book
containing national treatment guidelines, but not for disease protocols on posters
or pamphlets.
12 National Standard Treatment Guidelines (STGs) found in
some health facilities (indicator of STG implementation).
Policy was marked “yes” if the national STGs (published book) were observed in
more than two facilities visited.
13 National Formulary available Policy was marked “yes” if any national formulary was observed in any facility.
14 Generic prescribing policy in public sector Policy was marked “yes” if there was any initiative described to encourage generic
prescribing. Was not hypothesized to influence antibiotic use.
15 Generic substitution in public sector Policy was marked “yes” if generic substitution was both legal and seen to occur.
Was not hypothesized to influence antibiotic use.
16 Prescriber workload low or moderate Low/moderate workload defined as less than 60 patients per prescriber per day, as
reported by prescribers or as observed in patient registers.
Supply system
17 Public sector procurement limited to only EML medicines Policy was marked “yes” if public sector procurement limited to EML medicines was
reported at the central level and observed at the health facilities visited. Indicator of
implementation of the EML.
18 No medicines stock-out problems reported in the health
facilities visited
Policy was marked “yes” if health workers at the facilities visited stated that there
were no stock-out problems. Indicator of the quality of the supply system which
may impact on use.
Economic Policies
19 NO Drug sales revenue used to supplement prescriber
income
Policy was marked “no” if prescribers were observed selling drugs in the public
sector, as was the case in one country in 1 year.
20 No registration or consultation fee All countries stated that they dispensed drugs free of charge to all patients in
public facilities if medicines were available, but some charged registration or
consultation fees which could be perceived by patients as payment for treatment.
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correlation between the results of different situational
analyses done in the same country, a sensitivity analysis
was done by restricting the regression analysis to the lat-
est situational analysis of the country.
The impact of country economic status was assessed
by including Gross National Income per capita (GNIpc)
into multiple linear regression analyses and by repeating
the regression analyses for countries with GNIpc above
and below the median of USD 2230.
Finally, in those countries where a situational analysis
was done twice, the mean difference between situational
analyses, for each of the six QUM indicators, was calcu-
lated to see whether there had been any change in QUM
over time, and whether any change was accompanied by
a corresponding change in the number of policies
implemented.
Results
Data were extracted from 20 situational analysis reports
covering all 11 countries of the WHO South-east Asia
region – two reports from eight countries in different
years, two reports from India (one North Indian and one
South Indian state in the same year) and one report each
from two countries (Democratic Peoples’ Republic
[DPR] of Korea and Indonesia). QUM data for all six in-
dicators were extracted from 15 country-visit reports,
with 1–2 QUM variables missing from four reports
(concerning injection use, prescribing from the Essential
Medicines List [EML] and antibiotic use in upper re-
spiratory tract infection [URTI] cases), and 5 out of six
QUM indicators missing from one early report
(Bangladesh 2010). A total of 206 public-sector health
facilities were visited (average of 10–11 public-sector
health facilities per country-visit, half of which were pri-
mary healthcare centres) and 30 prescriptions per facility
were examined to estimate five of the six QUM indica-
tors. The QUM indicator concerning the % URTI cases
treated with antibiotics was estimated from visits to 151
public-sector health facilities (average of 7–8 facilities
per country visit) with an average of 23 URTI prescrip-
tions examined per facility. In two countries (Sri Lanka
2010 and Bangladesh 2010) no data on antibiotic use in
URTI was available, in two countries (Bhutan 2011 and
Maldives 2011) data on antibiotic use in URTI was avail-
able in only two health facilities and in one country
(Indonesia 2011) from only three health facilities. Policy
data for all 25 indicators were extracted from all 20
country-visit reports.
Comparison of QUM indicators in countries with and
without specific policies
Table 4 shows the mean differences for each of the six
QUM indicators, and the average difference across all
six QUM indicators, between countries that did and did
not implement the 25 policies hypothesised to be associ-
ated with better use. Figure 1 shows the mean difference
(with 95% confidence interval)) across all six QUM indi-
cators for each of the 25 policies. Twenty-two out of 25
policies were associated with better QUM, although in
many cases the differences were small. Twelve policies
were associated with statistically significantly (p < 0.05)
better QUM of more than 3.6% – namely not charging
patients any user fee or copayment for medicines at the
point of care, undergraduate education of prescribers on
the national treatment guidelines (STGs), distribution of
STGs to health facilities (as demonstrated by finding
Table 3 Medicine Policy variables with information on how a policy was judged to be present or not (Continued)
Policies recommended to improve medicines usea Criteria to determine whether a policy was adopted (implemented or partially
implemented) in a country
21 No user fee or copayment at the point of care Although all countries officially dispensed drugs free of charge in public facilities,
some types of facility, generally hospitals, charged a user fee or co-payment for
drugs at the point of care.
Regulatory policies
22 Systemic antibiotics generally not available over-the-
counter (OTC)
Systemic antibiotics could be got OTC in all countries but were generally
unavailable in Bhutan and DPR Korea where the private sector is very small, and
effort is made to enforce the drug schedules.
23 Regulation of advertisements for OTC drugs medicines No countries were monitoring all drug promotional activities, but some did monitor
advertising of OTC drugs.
Human resource policies
24 Prescribing by doctors (as opposed to other staff) in public
primary care
Policy was marked “yes” if doctors were observed to be prescribing in the primary
care facilities visited. Where doctors were not prescribing paramedical staff or
nurses generally prescribed, although in one country unqualified staff sometimes
prescribed.
25 No prescribing by staff with less than 1 month’s training
in public primary care
Policy was marked “yes” if no unqualified staff were observed to prescribe.
aIncludes all the policy questions, hypothesised to act on the quality of medicines use, as hypothesised elsewhere [16, 17] and found in the situational analysis
reports [21]
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Table 4 Differences in medicine use between countries with and without each of 25 policies hypothesised to be associated with
better use
Policy Number of
countries with
policy
(out of 20)a
% URTI
cases
treated with
antibiotics
% patients
treated
with
antibiotics
% medicines
prescribed
from the
EML
% medicines
prescribed by
generic name
% patients
prescribed
multivitamins
% of
patients
prescribed
injections
Average % better
(+) medicines use
with policy
(95% CI)
Direction of better
medicines use:
More (+); Less (−)
Less (−) Less (−) More (+) More (+) Less (−) Less (−) Sign changed
where less use is
better use
No user fee for drugs
at most public health
facilities
17 −9.6 + 0.1 + 9.5 + 31.2 −7.5 + 0.8 9.5* (0.2 to 18.7)
Undergraduate
education of
prescribers on STGs
5 −15.9 −5.2 + 12.0 + 22.0 − 1.1 + 0.9 9.2* (2.1 to 16.4)
Systemic antibiotics
mostly not available
OTC
3 −16.0 − 5.2 + 12.0 + 22.0 − 1.3 + 1.4 9.2* (1.9 to16.4)
MOH unit on Rational
Use of Medicines
established
3 −17.3 −10.9 + 0.1 + 19.7 + 0.9 −6.9 9.0* (2.1 to 15.9)
Some public-sector
prescriber CME by
MOH
8 −7.5 −1.6 + 5.7 + 21.9 − 8.7 − 4.8 8.4* (2.7 to 14.0)
Advertisements for
OTC drugs monitored
7 −14.5 −3.8 + 4.0 + 15.5 − 2.0 − 8.3 8.0* (3.4 to 12.7)
Public sector generic
prescribing policy
9 −3.9 −1.6 + 9.8 + 35.1 + 0.4 + 2.2 8.0 (− 3.2 to 19.1)
No drug revenue for
public sector
prescribers
19 −19.1 −2.7 −2.2 + 18.8 − 7.0 −6.7 7.8* (0.1 to 15.5)
MOH prescribing
survey done in the last
2 years
7 −4.7 −1.2 + 4.6 + 28.6 + 2.7 − 7.7 7.4 (− 1.4 to 16.2)
STGs found in some
public health facilities
5 − 11.4 −9.7 + 6.1 + 17.8 + 1.4 + 2.4 6.9* (0.6 to 13.1)
No public-sector
registration or
consultation fee
12 −13.0 −3.3 + 5.6 + 15.2 + 2.5 − 5.6 6.7* (1.5 to 11.9)
Some public education
on medicines use in
the last 2 years
5 −11.7 −7.4 + 2.5 + 8.9 −5.0 + 2.4 5.5* (1.5 to 9.5)
DTCs in most public
referral hospitals
8 −1.7 + 3.2 −2.5 + 15.2 −9.3 − 10.3 5.1 (− 0.9 to 11.2)
Generic substitution in
the public sector
15 + 6.0 + 7.8 + 16.1 + 21.8 −2.8 + 0.4 4.4 (−5.2 to 14.0)
No drug stock-out
problems reported
9 −11.6 −3.8 −0.1 − 1.4 −2.3 − 7.9 4.5* (0.1 to 8.0)
National Formulary
available
7 −8.7 −0.7 −3.4 + 6.1 − 5.9 − 3.7 3.6* (0.2 to 7.1)
National EML updated
in the last 2 years
12 −6.0 −0.7 + 16.1 − 0.4 + 1.2 + 2.2 3.2 (− 2.4 to 8.7)
Undergraduate
education of doctors
on the EML
6 −9.9 + 0.6 −3.5 + 1.7 −3.7 −6.8 3.0 (−0.9 to 6.9)
No public-sector un
qualified prescribers
18 −5.8 −6.5 + 8.4 + 9.8 + 8.4 + 8.6 2.3 (−4.5 to 9.0)
National STG updated
in the last 2 years
7 + 5.8 + 6.9 + 6.9 + 20.1 + 5.5 − 1.0 1.6 (−6.7 to 10.0)
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them in facilities), a Ministry of Health (MOH) unit ded-
icated to promoting QUM, continuing education on
prescribing for health workers by MOH, general
non-availability of systemic antibiotics over-the-counter
(OTC), monitoring of advertisements for OTC medi-
cines, no revenue from medicine sales for public sector
prescribers, having no stock-out problems, public
education and having a national formulary. For the 22
(out of 25) policies associated with better overall
QUM of more than 1%, 96 (73%) of a possible 132
comparisons (6 QUM indicators × 22 policies) were
associated with better QUM.
Table 4 Differences in medicine use between countries with and without each of 25 policies hypothesised to be associated with
better use (Continued)
Policy Number of
countries with
policy
(out of 20)a
% URTI
cases
treated with
antibiotics
% patients
treated
with
antibiotics
% medicines
prescribed
from the
EML
% medicines
prescribed by
generic name
% patients
prescribed
multivitamins
% of
patients
prescribed
injections
Average % better
(+) medicines use
with policy
(95% CI)
National AMR
Containment Strategy
4 −1.3 −3.7 −10.0 + 2.2 − 3.4 − 8.3 1.5 (− 3.4 to 6.4)
Public procurement
limited to EML drugs
only (excl. DPRK)
15 + 12.6 + 12.5 + 15.5 + 22.3 + 0.2 + 3.4 1.5 (− 10.1 to 13.1)
National Drug
Information Centre
2 + 7.2 −1.5 −3.9 + 11.6 + 3.4 + 15.7 − 2.8 (− 10.1 to 4.4)
Public sector PHC
prescribing by doctors
13 + 1.9 + 3.5 −2.3 −10.3 −4.0 + 5.8 −3.3 (− 7.1 to 0.4)
Prescriber patient
load moderate or
low (< 60 patients
/prescriber/day)
12 − 10.9 −8.7 −5.4 −6.3 + 27.2 + 7.9 − 4.5 (− 15.5 to 16.5)
*p ≤ 0.05
aSample size applies to the number of countries (out of 20) that had adopted the policy. The number of countries with and without policies for each individual
QUM indicator varies slightly as certain QUM indicators were not measured in 5 country visits
OTC Over-the-counter, STG Standard treatment guidelines, MOH Ministry of health, CME Continuing medical education, DTC Drug and therapeutic committee, EML
Essential medicines list, AMR Antimicrobial resistance, DPRK Democratic People’s Republic of Korea (which had no published EML)
Fig. 1 Differences in medicines use between countries with and without medicines policies. STG = Standard Treatment Guidelines; OTC = Over-
the-Counter; MOH =Ministry of Health; CME = Continuing Medical Education; DTC = Drug and Therapeutic Committee; EML = Essential Medicines
List; AMR = Antimicrobial Resistance; PHC = Primary Health Care
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Some policies had large effects on one particular
QUM indicator, but not on overall use (as judged by
six QUM indicators). Generic prescribing policies
were associated with greater generic prescribing;
implementing the national EML (as indicated by hav-
ing an updated EML and limiting public procurement
to EML drugs) was associated with greater prescribing
of EML medicines. However, low to modest prescriber
workload (as defined by seeing less than 60 patients
per day) was not associated with better overall QUM,
although it was associated with lower antibiotic use.
Effects of multiple policies and national wealth
Figure 2 shows a scatter plot of the composite QUM indi-
cator and the number of policies implemented (out of 22
policies associated with better QUM) for 20 situational ana-
lysis visits (country-years). There was moderate to strong
positive correlation between the number of essential medi-
cines policies implemented and the composite QUM indi-
cator (r = 0.71, r2 = 0.50, p < 0.05). In sensitivity analyses
(not shown graphically) the correlation increased when
GNIpc was included in the regression analysis (r = 0.75, r2
= 0.57, p < 0.05) and the correlation was moderate to strong
in the 10 country-visits with GNIpc above USD 2230 (r =
0.76, r2 = 0.58, p < 0.05) and below USD 2230 (r = 0.69, r2 =
0.48, p < 0.05). Furthermore, confining the regression ana-
lysis to data from the most recent situational analyses in 12
states (all 11 countries including 2 Indian states), in order
to take account of possible clustering of results from the
same site, also showed moderate to strong correlation
between the composite QUM indicator and the number of
essential medicines policies (r = 0.71, r2 = 0.50, p < 0.05).
Figures 3, 4, 5, 6, 7 and 8 show the scatter plots
for the individual QUM indicators versus policy im-
plementation. Regression analyses of individual QUM
indicators and the number of policies (out of 22) im-
plemented showed that with an increasing number of
essential medicines policies implemented there was:
an increase in the % prescribed medicines belonging
to the EML (r = 0.46, r2 = 0.21, p > 0.05) (Fig. 3); an
increase in the % medicines prescribed by generic
name (r = 0.62, r2 = 0.38, p < 0.05) (Fig. 4); a decrease
in the % patients prescribed injections (r = − 0.24, r2 =
0.06, p > 0.05) (Fig. 5) and a decrease in the % URTI
cases prescribed antibiotics (r = − 0.42, r2 = 0.18, p >
0.05) (Fig. 6). There was virtually no change in the %
patients treated with antibiotics (r = − 0.1, r2 = 0.01,
p > 0.05) (Fig. 7) or vitamins (r = − 0.1, r2 = 0.02, p >
0.05) (Fig. 8) with increasing number of policies im-
plemented. In a sensitivity analysis where policies not
hypothesised to influence antibiotic use were excluded
(2 policies on generic prescribing and substitution
and 3 policies on EML implementation), a stronger
association was found between the number of policies
(out of 17) implemented and the % URTI cases pre-
scribed antibiotics (r = − 0.49, r2 = 0.24, p < 0.05).
Changes over time
In seven of the eight countries where a situational ana-
lysis had been done twice, separated by a period of 3–
Fig. 2 Scatter plot of composite QUM score versus number of policies (out of 22) implemented
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Fig. 3 % prescribed medicines from the Essential Medicines List versus number of policies (out of 22) implemented
Fig. 4 % medicines prescribed by generic name versus number of policies (out of 22) implemented
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5 years, the average mean differences over time for
the six individual QUM indicators and the average
mean difference over the six QUM indicators, to-
gether with any change in the number of policies im-
plemented are shown in Table 5. The data for
Bangladesh were excluded because five of the six
QUM indicators were missing from the first situ-
ational analysis in 2010. The data show a significant
improvement in QUM together with increased policy
implementation in Thailand, while in other countries
there was no significant change in QUM and policy
implementation. However, the small sample sizes
Fig. 5 % patients prescribed injections versus number of policies (out of 22) implemented
Fig. 6 % Upper Respiratory Tract Infection cases prescribed antibiotics versus number of policies (out of 22) implemented
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(concerning health facilities and patient encounters)
preclude further interpretation of the data.
Discussion
This study has two important findings. Firstly, some pol-
icies were associated with significantly better QUM; and
secondly the more of these policies a country imple-
mented the better was the QUM.
Policies statistically significantly associated with more
than 7% better overall QUM were: not charging patients
any user fee or co-payment for medicines at the point of
care; implementation of STGs through undergraduate
Fig. 7 % patients prescribed antibiotics versus number of policies (out of 22) implemented
Fig. 8 % patients prescribed vitamins versus number of policies (out of 22) implemented
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education of prescribers and adequate distribution (as
indicated by finding STGs available at health facilities);
an MOH unit dedicated to monitoring and promoting
QUM; continuing medical education (CME) on prescrib-
ing for health workers by MOH; limiting the OTC avail-
ability of systemic antibiotics; not allowing public sector
prescribers to gain revenue from the sales of medicines;
and monitoring advertisements of OTC medicines.
Other policies that had a significant but smaller associ-
ation with better QUM included: more efficient drug
supply system (as indicated by no stock-out problems
reported); availability of a national formulary; public
education programs on medicines use; and not charging
patients any registration or consultation fee at health
facilities.
The policies associated with better QUM in this study
are similar to those policies associated with better QUM
in an analysis of global secondary data [16, 17] (exclud-
ing those policies which were not commonly measured
in both studies). The one exception was that CME was
done by MOH, and was associated with better QUM in
this study, but may not have been done by MOH in
countries included in the previous analysis of global
data, where CME was associated with poorer QUM.
The effectiveness of similar interventions has been
reported elsewhere, including: education of prescribers
[4, 5] and the public [26], an MOH unit dedicated to
promoting QUM [27], administrative interventions
such as hospital drug and therapeutic committees
(DTCs) [28, 29], non-allowance of prescriber income
from drug sales [30], non-allowance of antibiotics
OTC [31], and monitoring of drug promotional activ-
ities [32]. As found in analysis of global data where
provision of medicines free of charge was associated
with better use [16, 17], so in this study not charging
patients any fees for medicines (or fees that could be
construed by patients as being for medicines e.g.
registration and consultation fees) was associated with
better use.
There was a significant moderate to strong positive
correlation between the number of policies
implemented and the composite QUM (over six indi-
cators), and for two of the individual QUM indicators
(% URTI cases prescribed antibiotics and % medicines
prescribed by generic name). While the effect sizes
were small for individual policies (< 10%), the effect
sizes associated with implementation of multiple pol-
icies were large (30–95% over different QUM indica-
tors) and comparable with the largest intervention
effects reported elsewhere [4, 5]. We believe that the
data on the possible impacts of multiple policies are
important and likely to reflect a causal association.
This is the second time we have found the correla-
tions between numbers of implemented policies and
better QUM measures, and these analyses were conducted
in different and independent data-sets [16, 17].
Increased effect sizes with multiple (as opposed to
single interventions) have been reported in many litera-
ture reviews [4, 5, 33–35]. The correlations between the
composite QUM indicator and the number of policies
implemented remained strong in both wealthier and
poorer countries when the regression analysis was
repeated for countries with a GNIpc above and below
the median of USD 2230. This finding together with the
fact that there was no correlation between GNIpc and
the number of policies implemented suggests that it is
likely that the better QUM seen with increasing policy
implementation was due to the policies themselves and
not due to wealth, as has been found elsewhere [16, 17].
The apparent improvement in QUM in association
with increased policy implementation over time seen in
Thailand may be a chance finding since the number of
facilities was small and the same facilities were not
visited during both visits. Nevertheless, Thailand in-
creased its policy implementation more than other
countries over the time-period and similar results have
been reported elsewhere [36, 37]. Therefore, it is sug-
gested that the method used in this study to measure
QUM in relation to policy implementation may be a
good method to monitor country progress on promoting
QUM.
The data analysed in this study were collected from all
countries during 2-week periods using a pre-designed
workbook tool by government staff with facilitation from
WHO, were discussed in each country and a report pro-
duced and published on WHO/SEARO website for
future use [21]. The approach was mandated by Member
States [38, 39] and proved relatively cheap and quick, so
enabling government participation and action. This
study further shows that the data collected from this ap-
proach is sufficient for regional analysis and develop-
ment of a regional approach to promote better QUM.
Limitations
Although there were moderate to strong correlations
between medicines use and policy implementation in
this study, causality cannot be proved and may be
due to co-interventions. Small sample sizes disallowed
multi-variable analyses. Nevertheless, these are the
best data available on policy effectiveness in the pub-
lic sector in South-East Asia given the absence in all
countries of national longitudinal data which could be
used to perform time series analysis to show associ-
ation or possibly prove causality. It is acknowledged
that much health care is provided in the private sec-
tor but there was insufficient data to investigate this.
Nevertheless, the findings are very relevant since
many prescribers work in both the public and private
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sectors and many private-sector prescribers copy
public-sector ones e.g. private general practitioners
copying public-sector specialists.
The policy data, recorded in the situational analysis
country reports [21], was collected by direct observation
and discussion with health officials and health facility
staff during the country situational analysis visits and
thus may be more accurate than data relying on MOH
questionnaires, as used elsewhere [16, 17]. Nevertheless,
there may be some misclassification since relatively few
health facilities were visited and it was not always easy
to interpret whether a policy was implemented or not.
For example, there was enormous variation between
countries and between health facilities in the same coun-
try concerning hospital DTC activities, and the content
and extent of prescriber CME and public education pro-
vided by the MOH. Some policies measured in this study
are likely to be effective through association with other
health system factors and policies. For example, the gen-
eral lack of availability of systemic antibiotics OTC in
Bhutan and DPR Korea may be due to a lack of private
sector as well as regulatory controls. The policy “no
stock-outs reported” was assumed to reflect better drug
supply which might then impact on QUM. However, a
situation of “no stock-outs” could itself result from bet-
ter QUM.
The prescribing (QUM) data were collected by direct
examination of treatment in 30 outpatient patient
encounters (plus 10–30 URTI cases where measured)
per facility on the day of the visit using the INRUD/
WHO methodology [23, 24]. Since all six QUM indica-
tors were collected in 15 (75%) of the 20 country situ-
ational analysis visits, the QUM data may be more
robust than what we used in other work, where we
relied on previously published surveys with on average
only three QUM indicators per country [16]. Neverthe-
less, while every effort was made to collect the data in a
standard way, the variation between countries in docu-
mentation of patient treatment and the small sample
sizes involved may have resulted in some inaccuracies in
the results. Furthermore, some indicators such as injec-
tion use and antibiotic use in URTI cases could not be
measured in some countries and in some health facilities
within a country. However, any inaccuracies in the
QUM and policy data would tend to weaken the correla-
tions observed.
Another serious weakness is that the QUM measure-
ments were based on small convenience samples (by
MOH) of on average 10–11 public health facilities per
country visit. Thus, the surveys were not generalisable to
whole countries and no benchmarking of country per-
formance can be done using these data. Nevertheless,
implementation of some policies was judged by observa-
tion of what occurred in the health facilities where
QUM surveys were done, and this may account for the
stronger correlation between policy implementation and
QUM seen in this study compared to previous analyses
[16, 17].
Conclusions
Irrational use of medicines is a serious problem in
South-East Asia. Essential medicines policies were found
to be associated with better QUM and it is recom-
mended that all countries: implement (through adequate
education and distribution) national STGs, EML and
formulary; establish an MOH unit dedicated to QUM;
conduct CME on prescribing for health workers under
close supervision of MOH; limit OTC availability of sys-
temic antibiotics; disallow public sector prescribers to
gain revenue from the sales of medicines; monitor adver-
tisements of OTC medicines; run public education cam-
paigns on QUM; do not charge patients user fees or
co-payments for medicines at the point of care; and in-
vest in a more efficient drug supply system. The situ-
ational analysis approach allows the relatively quick and
cheap collection of data on QUM and policy implemen-
tation which can be used to monitor progress and plan
future action.
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